Celltrion showcases promising results in phase III study for CT-P47, a biosimilar candidate of RoActemra® (tocilizumab) in patients with rheumatoid arthritis (RA) at EULAR 2024
CT-P47 was highly similar in terms of efficacy and safety to the reference product RoActemra®…